Institution
University College Cork
Education•Cork, Ireland•
About: University College Cork is a education organization based out in Cork, Ireland. It is known for research contribution in the topics: Population & Irish. The organization has 12056 authors who have published 28452 publications receiving 958414 citations. The organization is also known as: Coláiste na hOllscoile Corcaigh & National University of Ireland, Cork.
Topics: Population, Irish, Gut flora, Microbiome, Casein
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The results suggest that the gut microbiome has a role in the cycle of metabolic dysfunction associated with olanzapine, and could represent a novel therapeutic target for preventing antipsychotic-induced metabolic disease.
Abstract: The atypical antipsychotic olanzapine is often associated with serious metabolic side effects including weight gain and increased visceral fat. These adverse events are a considerable clinical problem and the mechanisms underlying them are multifactorial and poorly understood. Growing evidence suggests that the gut microbiota has a key role in energy regulation and disease states such as obesity. Moreover, we recently showed that chronic olanzapine altered the composition of the gut microbiome in the rat. It is thus possible that treatments that alter gut microbiota composition could ameliorate olanzapine-induced weight gain and associated metabolic syndrome. To this end, we investigated the impact of antibiotic-induced alteration of the gut microbiota on the metabolic effects associated with chronic olanzapine treatment in female rats. Animals received vehicle or olanzapine (2 mg kg−1 per day) for 21 days, intraperitoneal injection, two times daily. Animals were also coadministered vehicle or an antibiotic cocktail consisting of neomycin (250 mg kg−1 per day), metronidazole (50 mg kg−1 per day) and polymyxin B (9 mg kg−1 per day) by oral gavage, daily, beginning 5 days before olanzapine treatment. The antibiotic cocktail drastically altered the microbiota of olanzapine-treated rats, and olanzapine alone was also associated with an altered microbiota. Coadministration of the antibiotic cocktail in olanzapine-treated rats attenuated: body weight gain, uterine fat deposition, macrophage infiltration of adipose tissue, plasma free fatty acid levels, all of which were increased by olanzapine alone. These results suggest that the gut microbiome has a role in the cycle of metabolic dysfunction associated with olanzapine, and could represent a novel therapeutic target for preventing antipsychotic-induced metabolic disease.
199 citations
••
TL;DR: In this paper, four commercially available natural products (olive leaf extract, lutein, sesamol and ellagic acid) were investigated for in vitro antioxidant properties using the DPPH, ABTS +, ferric reducing antioxidant capacity (FRAP), oxygen reducing antioxidant Capacity (ORAC) and β-carotene-linoleic acid assays.
198 citations
••
University College London1, University College Cork2, Karolinska University Hospital3, Paris Descartes University4, French Institute of Health and Medical Research5, University Medical Center Utrecht6, Uppsala University7, Duke University8, Erasmus University Rotterdam9, Helsinki University Central Hospital10
TL;DR: The findings suggest that bumetanide as an add-on to phenobarbital does not improve seizure control in newborn infants who have hypoxic ischaemic encephalopathy and might increase the risk of hearing loss, highlighting the risks associated with the off-label use of drugs in newborn babies before safety assessment in controlled trials.
Abstract: Summary Background Preclinical data suggest that the loop-diuretic bumetanide might be an effective treatment for neonatal seizures. We aimed to assess dose and feasibility of intravenous bumetanide as an add-on to phenobarbital for treatment of neonatal seizures. Methods In this open-label, dose finding, and feasibility phase 1/2 trial, we recruited full-term infants younger than 48 h who had hypoxic ischaemic encephalopathy and electrographic seizures not responding to a loading-dose of phenobarbital from eight neonatal intensive care units across Europe. Newborn babies were allocated to receive an additional dose of phenobarbital and one of four bumetanide dose levels by use of a bivariate Bayesian sequential dose-escalation design to assess safety and efficacy. We assessed adverse events, pharmacokinetics, and seizure burden during 48 h continuous electroencephalogram (EEG) monitoring. The primary efficacy endpoint was a reduction in electrographic seizure burden of more than 80% without the need for rescue antiepileptic drugs in more than 50% of infants. The trial is registered with ClinicalTrials.gov, number NCT01434225. Findings Between Sept 1, 2011, and Sept 28, 2013, we screened 30 infants who had electrographic seizures due to hypoxic ischaemic encephalopathy. 14 of these infants (10 boys) were included in the study (dose allocation: 0·05 mg/kg, n=4; 0·1 mg/kg, n=3; 0·2 mg/kg, n=6; 0·3 mg/kg, n=1). All babies received at least one dose of bumetanide with the second dose of phenobarbital; three were withdrawn for reasons unrelated to bumetanide, and one because of dehydration. All but one infant also received aminoglycosides. Five infants met EEG criteria for seizure reduction (one on 0·05 mg/kg, one on 0·1 mg/kg and three on 0·2 mg/kg), and only two did not need rescue antiepileptic drugs (ie, met rescue criteria; one on 0·05 mg/kg and one on 0·3 mg/kg). We recorded no short-term dose-limiting toxic effects, but three of 11 surviving infants had hearing impairment confirmed on auditory testing between 17 and 108 days of age. The most common non-serious adverse reactions were moderate dehydration in one, mild hypotension in seven, and mild to moderate electrolyte disturbances in 12 infants. The trial was stopped early because of serious adverse reactions and limited evidence for seizure reduction. Interpretation Our findings suggest that bumetanide as an add-on to phenobarbital does not improve seizure control in newborn infants who have hypoxic ischaemic encephalopathy and might increase the risk of hearing loss, highlighting the risks associated with the off-label use of drugs in newborn infants before safety assessment in controlled trials. Funding European Community's Seventh Framework Programme.
198 citations
••
TL;DR: Cheese contains a low level of citrate, metabolism of which by Streptococcus diacetylactis leads to the production of di acetyl, which contributes to the flavor and is responsible for the limited eye formation characteristic of such cheeses.
Abstract: Fermentation of lactose to lactic acid by lactic acid bacteria is an essential primary reaction in the manufacture of all cheese varieties. The reduced pH of cheese curd, which reaches 4.5 to 5.2, depending on the variety, affects at least the following characteristics of curd and cheese: syneresis (and hence cheese composition), retention of calcium (which affects cheese texture), retention and activity of coagulant (which influences the extent and type of proteolysis during ripening), the growth of contaminating bacteria. Most (98%) of the lactose in milk is removed in the whey during cheesemaking, either as lactose or lactic acid. The residual lactose in cheese curd is metabolized during the early stages of ripening. During ripening lactic acid is also altered, mainly through the action of nonstarter bacteria. The principal changes are (1) conversion of L‐lactate to D‐lactate such that a racemic mixture exists in most cheeses at the end of ripening; (2) in Swiss‐type cheeses, L‐lactate is meta...
198 citations
••
TL;DR: It would be more appropriate to recast the debate between ‘hard’ and ‘soft’ research approaches at a macro level in order to accommodate different research agenda and recognize the strengths within each tradition.
Abstract: The debate between ‘hard’ and ‘soft’ research approaches continues in the IS field, but with little prospect of resolution. The debate is typically characterized by tendentious arguments as advocates from each approach offer a somewhat one-sided condemnation of the counterpart from the inimical research tradition. This paper begins by relating two fictitious tales which serve to highlight the futility of research conducted at the extremity of each research approach. The dichotomies which characterize these rival factions are also summarized. The debate is then framed in terms of the polarization problem whereby IS researchers are divided geographically and paradigmatically into ‘hard’ and ‘soft’ camps. A variety of different strategies have been proposed for resolving the debate and these are discussed in detail. They are grouped into four categories, referred to as supremacism, isolationism, integration, and pluralism. Finally, the paper contends that the debate cannot be resolved, and offers the metaphor of magnetic polarity as a means of reflecting this. The paper concludes by arguing that it would be more appropriate to recast the debate at a macro level in order to accommodate different research agenda and recognize the strengths within each tradition.
198 citations
Authors
Showing all 12300 results
Name | H-index | Papers | Citations |
---|---|---|---|
Stephen J. O'Brien | 153 | 1062 | 93025 |
James J. Collins | 151 | 669 | 89476 |
J. Wouter Jukema | 124 | 785 | 61555 |
John F. Cryan | 124 | 723 | 58938 |
Fergus Shanahan | 117 | 705 | 51963 |
Timothy G. Dinan | 116 | 689 | 60561 |
John M. Starr | 116 | 695 | 48761 |
Gordon G. Wallace | 114 | 1267 | 69095 |
Colin Hill | 112 | 693 | 54484 |
Robert Clarke | 111 | 512 | 90049 |
Douglas B. Kell | 111 | 634 | 50335 |
Thomas Bein | 109 | 677 | 42800 |
Steven C. Hayes | 106 | 450 | 51556 |
Åke Borg | 105 | 444 | 53835 |
Eamonn Martin Quigley | 103 | 685 | 39585 |